Mohamed Gendy, MD
Ophthalmology · Fort Wayne, INNPI 1508183427
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 82 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations.
Across 82 payments — averaging $43.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$755
- Astellas Pharma US Inc$720
- AbbVie$484
- Harrow Eye, LLC$310
- Apellis Pharmaceuticals, Inc.$296
- Alimera Sciences, Inc.$282
- plus $734 from 6 others
Across 173 payments — averaging $4677.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$682K
- Regeneron$127K
What the payments were for
- Food & beverage$3,582100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 10 | $755 |
| Astellas Pharma US Inc | 15 | $720 |
| AbbVie(2 entities) | 14 | $484 |
| Harrow Eye, LLC | 5 | $310 |
| Apellis Pharmaceuticals, Inc. | 6 | $296 |
| Alimera Sciences, Inc. | 11 | $282 |
| Genentech USA, Inc. | 13 | $270 |
| Novartis | 4 | $150 |
| Spark Therapeutics, Inc. | 1 | $111 |
| ANI Pharmaceuticals, Inc. | 1 | $103 |
| Dutch Ophthalmic, USA | 1 | $80 |
| Eyepoint US, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,582 in reported general payments places this provider in the 70th percentile of 266 ophthalmology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 42 | $1,915 |
| Brimonidine Tartrate | 59 | $1,363 |
| Latanoprost | 43 | $733 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 28 | $500 |
| Ketorolac Tromethamine | 19 | $474 |
| Dorzolamide Hcl | 11 | $210 |
| Timolol Maleate | 12 | $23 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Fort Wayne
- Adeel KhanFort Wayne$4K
- James KimFort Wayne$4K
- Shamik BafnaLafayette$505K
- Kevin WaltzIndianapolis$199K
- Janet HummerIndianapolis$96K
- Francis PriceIndianapolis$67K
- Omar DukarEvansville$43K
- Gerald RoperBatesville$34K
- Dwight SilveraEvansville$28K
- Michael OrrIndianapolis$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.